DarioHealth Corp. (“DarioHealth” or “Dario”) (Nasdaq: DRIO), a leading, global digital therapeutics company, today announced an alliance with DigitalHealth.London (“DH.L”) as part of its UK Israel Dangoor Health Initiative (the “Initiative”), which aims to partner leading Israeli digital health companies with the UK National Health Service (NHS) to benefit patients.
| NEW YORK and CAESAREA, Israel, Aug. 15, 2019 /PRNewswire/ -- DarioHealth Corp. (“DarioHealth” or “Dario”) (Nasdaq: DRIO), a leading, global digital therapeutics company, today announced an alliance with DigitalHealth.London (“DH.L”) as part of its UK Israel Dangoor Health Initiative (the “Initiative”), which aims to partner leading Israeli digital health companies with the UK National Health Service (NHS) to benefit patients.
Dario was selected by DH.L to help bring its highly regarded digital therapeutics technology to assist NHS patients in better managing their chronic health conditions, such as pre-diabetes, diabetes and hypertension, among other chronic conditions. The Initiative is a partnership between the UK Israel Tech Hub, which aims to help British companies partner with cutting-edge technology companies in Israel; DigitalHealth.London, a collaborative that helps high-potential, digital health start-up companies connect with the NHS; and Dangoor Education. DH.L is well placed to accelerate the adoption and scaling of digital innovations across the NHS. The Initiative will help facilitate additional access for DarioHealth to key UK clinicians, academic institutes, healthcare system experts and industries in order to better understand the needs of patients and the NHS. “With 25 per cent of middle-aged adults suffering from hypertension and 2.6 million people diagnosed with diabetes, the NHS needs the very best in digital innovation in order to manage chronic disease conditions successfully, now and into the future,” said Dror Bacher, Chief Operating Officer at DarioHealth Corp. “I recently had the pleasure of meeting key NHS clinicians and influencers and learned first-hand about the challenges and opportunities that they’re experiencing within the healthcare sector. DarioHealth is well positioned to offer quality digital therapeutic interventions for managing chronic conditions and looks forward to exploring opportunities for integration and partnership with both primary and secondary care providers. Through our collaboration, we will examine the best ways to develop new Dario digital therapeutic solutions for people with chronic conditions within the framework of the NHS.” A key differentiator of Dario’s performance-based platform is its emphasis on behavioral engagement with users, through the offering of personalised interventions, which is a unique approach in the digital therapeutics’ arena. DarioHealth’s platform focuses on the user’s needs, experience and satisfaction. We believe that this approach disrupts the traditional approach used by most healthcare companies and makes the Dario platform the most popular product by people managing diabetes and pre-diabetes. DarioHealth continues to find new, innovative ways to assist its users in improving their health through ongoing analysis of clinical-data studies and the application of new digital solutions. By delivering personalized, evidence-based interventions driven by precision data analytics, high-quality software and personalised coaching, DarioHealth has a dynamic health management approach that empowers individuals to make informed, data-driven choices that improve their short and long-term health. Dario’s membership programs offer professional coaching to individuals with pre-diabetes, diabetes and hypertension to provide them a clear and timely view of their condition in a user-friendly format directly on their iPhone or Android mobile device. DarioHealth’s most recently introduced digital product, the Dario Blood Pressure Monitoring System™, assists hypertension patients in managing their blood pressure throughout the day, further solidifying the company’s presence in the hypertension management market. About DarioHealth Corp. DarioHealth Corp. (Nasdaq: DRIO) is a leading, global digital therapeutics company revolutionising the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we empower individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Our cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric Dario mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions via the Dario mobile app, please go to: http://mydario.com/ Cautionary Note Regarding Forward-Looking Statements This news release and the statements of representatives and partners of DarioHealth Corp. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” are intended to identify forward-looking statements. “For example, when Dario states that it will bring its highly regarded digital therapeutics technology to assist NHS patients in better managing their chronic health conditions, that the Initiative will help facilitate additional access for DarioHealth to key UK clinicians, academic institutes, healthcare system experts and industries in order to better understand the needs of patients and the NHS, that Dario’s approach of emphasizing behavioral engagement with users disrupts the traditional approach used by most healthcare companies and makes the Dario platform the most popular product by people managing diabetes and pre-diabetes, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialisation or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact: Media Inquiries:
SOURCE DarioHealth Corp. | ||
Company Codes: NASDAQ-SMALL:DRIO, Berlin:LS1N, Stuttgart:LS1N |
View original content to download multimedia:
